A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Clinical trial NCT05581875 · NOT_YET_RECRUITING

Trial details

NCT number: NCT05581875
Sponsor: Hellenic Society of Hematology
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma Multiple Myeloma in Relapse Neoplasms Gammopathy, Monoclonal Paraproteinemias Blood Protein Disorders Haematologic Disease Corneal Disease Neoplasms, Plasma Cell

Start date: 2022-10-20
Primary completion: 2026-10-31
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.